DELTA FORCE is the first head-to-head phase 3 trial comparing a ... FORCE data in The Lancet is an exciting moment for the LEO Pharma team,” said Robert Spurr, EVP, LEO Pharma, North America ...

DELTA FORCE is the first head-to-head phase 3 trial comparing a systemic and investigational delgocitinib topical treatment for Chronic Hand Eczema (CHE).1 LEO Pharma A/S, a global leader in ...

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 61.7% of Atyr PHARMA shares are held by institutional investors. 20.6% of MiNK Therapeutics shares are held by ...

Rayes as Head of Commercial, Global Efzofitimod Franchise. Ms. Rayes brings over 25 years of experience building and leading commercial organizations at biotechnology and pharmaceutical companies, ...

Bayer expects its pharmaceutical business to return to growth in 2027, unit President Stefan Oelrich said Monday. The German conglomerate is planning to launch new therapies — one that treats a ...

Gujarat-based drugmaker Intas Pharmaceuticals Ltd., which counts private equity firm ChrysCapital, Singapore state investment firm Temasek and Abu Dhabi Investment Authority (ADIA) as its investors, ...

A Triangle pharmaceutical firm is expanding its portfolio as its parent company completes a $500 million deal. © 2025 American City Business Journals. All rights ...

Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care therapies, plans to assume full ...

Bayer AG’s revenue will not plummet even though the company is facing patent expiries for some blockbuster drugs, according to its pharma head. “The patent cliff is more of a dent than a cliff ...

is pleased to announce the appointment of Dr. Rob Scott as Chief Medical Officer and Head of R&D with immediate effect. Cyrille Tupin, CEO of ABIONYX Pharma, commented: "We are excited to welcome ...

Ahmedabad: Intas Pharmaceuticals Ltd has announced a strategic exclusive licensing agreement with mAbxience (a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma ...

In a warning letter to the company's CEO and MD Nimish Chudgar, the US Food and Drug Administration (USFDA) has pointed out various manufacturing lapses at the Matoda-Sanand, Ahmedabad-based facility.